New research from Emory University evaluated immune responses after the 2023–24 COVID vaccine. The study, published in Science and Translational Medicine, followed 24 participants for six months and measured memory B cells, binding antibodies, and neutralizing antibodies. The 2023–24 vaccine was monovalent and designed to match the then-dominant Omicron XBB.1.5 variant; previous vaccines had been bivalent.
Laboratory tests showed the vaccine produced antibodies with a half-life of more than 500 days, so at least half remained detectable more than 16 months after vaccination. Participants also produced cross-reactive antibodies that recognized both the ancestral WA1 strain and XBB.1.5. The researchers said immune imprinting likely contributed to a 2.8-fold increase in these cross-reactive antibodies.
The paper notes that SARS-CoV-2 has caused more than 1.2 million deaths nationwide and has many mutations. It also lists groups at higher risk of severe disease, such as people with cancer, autoimmune disorders, stroke, obesity, and existing heart, kidney, lung, or liver conditions.
Difficult words
- memory B cells — White blood cell that remembers past infections
- binding antibodies — Protein that binds to a virus or germ
- neutralizing antibodies — Antibody that can stop a virus infecting cells
- monovalent — Designed to target one strain or variant
- bivalent — Designed to target two different strains together
- half-life — Time for half of a substance to disappear
- immune imprinting — When first immune exposure shapes later responses
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Which of the risk groups named in the article would you put first for vaccine access in your community, and why?
- If antibodies remain detectable for many months, how might that change people’s plans for booster shots?
- How would you feel about a vaccine made to match a single dominant variant versus one that targets two variants? Explain briefly.
Related articles
Simpler treatment trial for cryptococcal meningitis in Malawi
Cryptococcal meningitis kills many people in Sub‑Saharan Africa and mainly affects people with HIV. A Phase II trial in Lilongwe is testing a sustained‑release flucytosine pellet to make treatment easier, while clinicians warn that early testing and care remain vital.
Dopamine helps lock in new skills during sleep
A study from the University of Michigan finds that dopamine neurons become active during NREM sleep soon after a person learns a movement. Their activity, together with sleep spindles, strengthens motor memories and improves skills after sleep.
